

Structure of the hypothetical *Mycoplasma* protein MPN555 suggests a chaperone function

Ursula Schulze-Gahmen,^a Shelly Aono,^{a,‡} Shengfeng Chen,^a Hisao Yokota,^a Rosalind Kim^a and Sung-Hou Kim^{a,b*}

^aBerkeley Structural Genomics Center, Physical Biosciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA, and ^bDepartment of Chemistry, University of California, Berkeley, California 94720, USA

‡ Current address: Department of Anatomy, Physiology and Pharmacology, Auburn University, Auburn, AL 36849, USA.

Correspondence e-mail: shkim@lbl.gov

The crystal structure of the hypothetical protein MPN555 from *Mycoplasma pneumoniae* (gi|1673958) has been determined to a resolution of 2.8 Å using anomalous diffraction data at the Se-peak wavelength. Structure determination revealed a mostly α -helical protein with a three-lobed shape. The three lobes or fingers delineate a central binding groove and additional grooves between lobes 1 and 3 and between lobes 2 and 3. For one of the molecules in the asymmetric unit, the central binding pocket was filled with a peptide from the uncleaved N-terminal affinity tag. The MPN555 structure has structural homology to two bacterial chaperone proteins: SurA and trigger factor from *Escherichia coli*. The structural data and the homology to other chaperone proteins suggests an involvement in protein folding as a molecular chaperone for MPN555.

Received 10 June 2005

Accepted 14 July 2005

PDB Reference: MPN555,
1zxi, r1zxijsf.

1. Introduction

MPN555 is a hypothetical protein from *Mycoplasma pneumoniae*. Sequence similarity searches using *PSI-BLAST* (Altschul *et al.*, 1997) identified only five significant sequence homologs, all of which occur in *Mycoplasma* or *Ureaplasma* species. In addition, one very remote sequence homolog was identified: the C-terminal domain of a trigger factor from *Pseudomonas putida* (accession No. PF05698 in the Pfam database; Bateman *et al.*, 2000). Trigger factors are molecular chaperones with peptidylproline *cis-trans*-isomerase (PPIase) activities. The C-terminal domain of the *Escherichia coli* trigger factor appears to be critical for the chaperone activity of this protein (Kramer *et al.*, 2004) and its structure has been determined recently (Ferbitz *et al.*, 2004). The crystal structure of another bacterial trigger factor from *Vibrio cholerae* has also been published recently (Ludlam *et al.*, 2004). However, the sequence similarity between MPN555 and the C-terminal domain of the *E. coli* and *V. cholerae* trigger factors was not even recognized in *PSI-BLAST* searches. Since the three-dimensional structures of MPN555 sequence-homologous proteins are unknown, we determined the crystal structure of MPN555 to obtain some clues about the possible molecular function of this protein family.

2. Material and methods

2.1. Cloning, expression and purification

Primers (Life Tech, Bioneer, MWG or Operon) for PCR amplification from genomic DNA contained an *NdeI* restriction site in the forward primer (5'-CATATGGCTACAAATCTTAAATCAACCG-3') and a *BamHI* site in the reverse primer (5'-GGATCCTTAGTTTGGTAATTGTCCAGTTA-

ACGTTAAA-3'). PCR was performed using Deep Vent Polymerase (New England Biolabs Inc., Beverly, MA, USA) and genomic DNA. The PCR product was cloned into a pCR-BluntII-TOPO vector (Invitrogen Corporation, Carlsbad, CA, USA) and the gene insert was confirmed by DNA sequencing. The amplified TOPO vector was restricted with *NdeI* and *BamHI* and the gene insert was purified by agarose-gel electrophoresis extraction. This insert was ligated into pSKB3 (a gift from Steve Burley, Rockefeller University, New York, USA) digested with *NdeI* and *BamHI* and transformed into DH5 α . A plasmid containing the gene insert was confirmed and then transformed into BL21(DE3)pSJS1244 (Kim *et al.*, 1998).

MPN555 fusion protein was expressed in *Escherichia coli* strain BL21(DE3)pSJS1244 using an auto-inducible selenomethionyl medium (Studier, 2005). Cells grow in this medium uninduced to relatively high cell densities and are then induced automatically without addition of IPTG. For cell lysis, 3.5 g cell pellet was resuspended in 20 ml 50 mM Tris-HCl pH 7.5, 300 mM NaCl, 5 mM imidazole with 1 mM PMSF, 1 $\mu\text{g ml}^{-1}$ leupeptin, 2.5 $\mu\text{g ml}^{-1}$ pepstatin, 0.2 $\mu\text{g ml}^{-1}$ antipain, 1 $\mu\text{g ml}^{-1}$ chymostatin and 10 $\mu\text{g ml}^{-1}$ DNase I. Cells were disrupted by sonication, which was followed by centrifugation at 15 000g to remove cell debris. The supernatant was then spun at 60 000g for 30 min at 277 K to remove membrane proteins. The His-tagged fusion protein was then purified over a 7 ml cobalt affinity column (Talon resin; Clontech, Palo Alto, CA, USA) and eluted with 100 and 300 mM imidazole. Protein-containing fractions were combined and buffer-exchanged against 50 mM Tris-HCl pH 9.0, 1 mM EDTA, 5% glycerol prior to anion-exchange chromatography on a HQ20 Poros column (Applied Biosystems, Foster City, CA, USA), which was equilibrated in the same buffer and developed with an NaCl gradient. MPN555 eluted from the anion-exchange column in a single peak with a small shoulder at about 200 mM NaCl. Fractions from the main peak were combined and concentrated to 30 mg ml $^{-1}$ in 20 mM Tris pH 8.0, 1 mM EDTA, 2 mM DTT using an Ultrafree 10 kDa cutoff unit (Millipore Corporation, Bedford, MA, USA). The purity of the expressed protein was determined by SDS-PAGE to be ~99%. Dynamic light scattering (DynaPro 99, Proterion Corporation, Piscataway, NJ, USA) showed a single monodisperse peak (23% polydispersity), indicating homogeneity of the protein.

2.2. Crystallization and data collection

Screening for crystallization conditions was performed using the sparse-matrix method (Jancarik & Kim, 1991) with several screens from Hampton Research (Laguna Niguel, CA, USA). Several 96-well plates were used to set up the screens with the Hydra Plus One crystallization robot (Matrix Technologies, Hudson, NH, USA)

Table 1
X-ray diffraction data statistics.

Values in parenthesis are for the outermost resolution shell.

Wavelength (Å)	0.9795
Resolution (Å)	42.76–2.8 (2.95–2.80)
Redundancy	3.3 (3.1)
Unique reflections	40298
Completeness	96.5 (91.8)
$I/\sigma(I)$	6.7 (1.8)
R_{sym}^{\dagger} (%)	7.9 (47.2)

$\dagger R_{\text{sym}} = \sum_{hkl} \sum_i |I_i - \langle I \rangle| / \sum_i I_i$, where I_i is the intensity of the i th measurement of reflection hkl and $\langle I \rangle$ is the average intensity of the reflection.

using the sitting-drop vapor-diffusion method at room temperature. The best initial crystals were grown in 50 mM Bis-Tris pH 6.5, 50 mM ammonium sulfate, 30% pentaerythritol ethoxylate.

Very large crystals grew, but with multiple crystals intertwined. Addition of detergent eventually improved the crystals sufficiently to provide small single crystals for data collection. The best crystals were grown in 50 mM Bis-Tris pH 6.5, 60 mM ammonium sulfate, 35% pentaerythritol ethoxylate, 0.4 mM Zwittergent 3-14 at 295 K in sitting drops. The precipitant of the MPN555 crystallization is an effective cryoprotectant, so that crystals could be flash-cooled directly out of the crystallization drop without any further soaking. A Se peak-wavelength ($\lambda = 0.9795$) SAD data set was collected at the Macromolecular Crystallography facility beamline 5.0.2 at the Advanced Light Source (Lawrence Berkeley National Laboratory, Berkeley, CA, USA). A Quantum 4 CCD detector from Area Detector Systems Co. (ADSC, Poway, CA, USA) was used. The crystal-to-detector distance was set to 250 mm. In total, 360 images were collected (180 images for both direct and inverse beam) in 18 wedges with 1° oscillation range per image. A data set of 2.8 Å resolution was processed using the program *MOSFLM* (Collaborative Computational Project, Number 4, 1994). The crystal belongs to the monoclinic space group *C2*, with unit-cell parameters $a = 132.37$, $b = 45.59$,




Figure 1
Typical electron-density map centered on Glu176. The $2F_o - F_c$ map was contoured at 1.2σ . This illustration and all other ribbon and surface drawings were prepared using *PyMOL* (DeLano, 2002).

Table 2

Phasing and refinement statistics of the SAD X-ray diffraction data.

Phasing statistics	
Unit-cell parameters (Å, °)	$a = 132.37, b = 45.59,$ $c = 153.93, \beta = 111.40$
Se atoms found per AU	12
FOM (figure of merit)	0.24
FOM after density modification	0.55
Refinement statistics	
Unique reflections	38935
R factor (%)	24.9
$R_{\text{free}}^{\dagger}$ (%)	32.3
Residues per monomer	A, 192; B, 171; C, 192; D, 193
Residues per asymmetric unit	748
No. atoms per asymmetric unit	5919
Protein	5905
Water	14
R.m.s. deviations	
Bond distances (Å)	0.008
Angle deviations (°)	1.265
B_{average} (Å ²)	40.0
Ramachandran plot statistics	
Residues in most favored regions (%)	88.5
Residues in additional allowed regions (%)	11.4
Residues in disallowed regions (%)	0

[†] R_{free} calculated as for the R factor but on 7.5% of data excluded from refinement.

$c = 153.93$ Å, $\beta = 111.40^{\circ}$. With four molecules in the asymmetric unit, the solvent content of the crystal is 40%, with a Matthews coefficient of 2.13 Å³ Da⁻¹. A least-squares straight line from the Wilson plot approximates the B factor as around 65 Å². The data statistics are shown in Table 1.

2.3. Structure determination and refinement

12 out of 20 possible Se-atom positions were located using the program *HySS* from the *PHENIX* package (Grosse-Kunstleve & Adams, 2003) followed by phasing in *CNS* (Brünger *et al.*, 1998). Diffraction data and phases were imported into *RESOLVE* v.2.07 (Terwilliger, 2002) for density modification and model building. *RESOLVE* found non-crystallographic translational symmetry (NCS) relating two pairs of MPN555 molecules, which agrees with a strong peak at 0.5, 0.175, 0.5 in the native Patterson map. The partial model built by *RESOLVE* included 536 residues and resulted in an R_{free} of 46.5%. Further tracing and rebuilding was performed using the program *O* (Jones *et al.*, 1991) alternating with refinement in *CNS* and *REFMAC* v.5.2 (Murshudov *et al.*,




Figure 2

Secondary-structure annotated protein sequence of MPN555. The protein sequence of MPN555 is numbered from 1 to 193 and the N-terminal His-tag from *t1* to *t25*. α -Helices are drawn as rectangles and β -sheets as zigzag lines above the sequence.





Figure 3

Overall fold and surface representation of MPN555. Molecule *D* was chosen for the schematic drawings in this figure and Fig. 4 because it has the most complete N-terminal peptide originating from the affinity tag. (a) shows the arrangement of secondary structures into three lobes in the MPN555 fold. A peptide from the N-terminal His tag is bound in the central binding pocket. (b) shows a surface representation of the same molecules. Negatively charged surfaces are colored in red and positively charged surfaces in blue. Electrostatic surfaces were calculated using the program *APBS* (Baker *et al.*, 2001) in *PyMOL*.

1997). The model was built for two molecules and the remaining two molecules in the asymmetric unit were created using NCS operators. NCS restraints were included in the early stages of refinement, but were completely released in the later stages. The electron density for most parts of the molecules is well connected (Fig. 1). However, electron density for the N-terminal tag and linker sequence (25 residues, *t1*–*t25*; Fig. 2) varies enormously among the molecules, from almost invisible in molecule *B*, to untraceable fragments in molecules *A* and *C*, to clearly traceable in molecule *D*. The untraceable densities in some of the molecules may contribute to the relatively high *R* factor of this structure (Table 2). In addition, the low data redundancy and low $I/\sigma(I)$ in the high-resolution shell may contribute to the relatively high *R* factors. The final structure includes the following residues: *t12*–*t15*, *t22*–*A96*, *A102*–*A190*, *B5*–*B93*, *B103*–*B145*, *B149*–*B187*, *t14*–*t18*, *t23*–*C2*, *C5*–*C97*, *C102*–*C190*, *t14*–*D93*, *D100*–*D144* and *D150*–*D192* (Fig. 2).




Figure 4
Superposition of two structurally homologous proteins onto MPN555. (a) Parts of the N-terminal and C-terminal segments of SurA (PDB code 1m5y) were superimposed onto MPN555 with the program *PDBSET* from the *CCP4* suite using matrices suggested by the *DALI* search engine. The r.m.s.d. for 139 aligned residues is 4.7 Å. MPN555 is shown in red. The complete SurA protein is shown in blue. (b) A similar superposition of the C-terminal domain of *E. coli* trigger factor (PDB code 1w26) onto MPN555. The r.m.s.d. for 129 aligned residues is 3.5 Å. MPN555 is shown in red and the C-terminal domain of TF is shown in green.

3. Results and discussion

3.1. Structure description

The crystallized form of MPN555 includes the 193 amino acids of the complete protein and an additional 25 residues from the uncleaved N-terminal His tag (Fig. 2). Most of the protein residues are clearly defined in all four molecules in the asymmetric unit. Only residues in the loops between $\alpha 3$ and $\alpha 4$ and between $\alpha 5$ and $\alpha 6$ (Fig. 3a) are missing. The quality of the density for the N-terminal His tag varies enormously among the different molecules. Molecule *B* has no density for the tag, molecules *A* and *C* have density fragments that are difficult to interpret and molecule *D* shows quite clear density for residues *t14*–*t25* of the His tag. Two pairs of the four molecules in the asymmetric unit are very similar in structure, with an r.m.s. value on main-chain atoms of 0.6 Å for molecules *A* and *C*, and an r.m.s. value of 0.65 Å for molecules *B* and *D*. The other possible pairs (*A*–*B*, *A*–*D*, *B*–*C* and *D*–*C*) have larger structural differences in residues 22–27

and 42–50, leading to r.m.s. values of around 1.6 Å for all main-chain atoms. The structural differences are mostly located in loop regions and in a translational shift of the N-terminal segment of $\alpha 2$. MPN555 has mostly α -helical structure with two very small β -sheets (Fig. 3a). It has a trilobal shape in which the three lobes or fingers delineate a pocket or groove in the center of the molecule. The three lobes are made up of $\alpha 1$ and $\alpha 2$ (lobe 1), $\alpha 3$, $\alpha 4$, $\beta 1$ and $\beta 3$ (lobe 2) and $\alpha 5$, $\alpha 6$ and part of $\alpha 7$ (lobe 3). A small β -sheet extends away from the main part of the molecule. The central pocket of the protein is filled by residues from the N-terminal His tag in molecule *D*. There are two additional empty grooves between lobes 1 and 3 and between lobes 2 and 3. The shape of the molecule resembles a hand with thumb, pointer and middle finger extended and slightly curved.

3.2. Comparison with similarly folded structures

Despite the low sequence similarities found using *PSI-BLAST*, a search for proteins with structural similarity using *DALI* (Holm & Sander, 1996) revealed two proteins with significant structural homology. The *E. coli* protein SurA (PDB code 1m5y) and the *E. coli*

trigger factor (PDB code 1w26) both contain domains with structural similarity to MPN555 with *DALI Z* scores of 6.2 and 9.2, respectively. SurA protein facilitates the correct folding of outer membrane proteins in Gram-negative bacteria. It accomplishes this in the absence of ATP or other sources of chemical energy. The protein sequence is divided into four segments: an N-terminal segment, two peptidyl-prolyl isomerase (PPIase) segments and a C-terminal segment. The amino-terminal and carboxy-terminal segments together with the first PPIase segment form a core structural module and the second PPIase segment is a satellite domain tethered 30 Å from the core structure (Bitto & McKay, 2002). The MPN555 structure is homologous to the part of the core structure of SurA, which is composed of the N-terminal and C-terminal segments (Fig. 4a). Interestingly, the crystal contacts in the SurA structure show that peptides bind within a crevice of the core module that is equivalent to the binding pocket in MPN555, which is filled with the N-terminal tag in some of the molecules. In addition, it was found that the N- and C-terminal domains of SurA alone can be expressed *in vivo* and complement wild-type SurA activity (Behrens *et al.*, 2001). The fusion construct can be expressed as a recombinant protein in *E. coli*, is stable and can be purified (Bitto & McKay, 2002). Although the SurA sequence includes two PPIase domains, the PPIase activity is apparently dispensable for SurA function *in vivo* (or is encoded by redundant PPIase genes). SurA has a chaperone mechanism that is largely encoded in the non-PPIase domains of its sequence and this is the part that is structurally homologous to MPN555.

The second protein with structural homology to MPN555 is the *E. coli* ribosome-associated trigger factor (TF). The trigger factor from *V. cholerae* (Ludlam *et al.*, 2004), however, shows no significant structural similarity to MPN555 (*DALI Z* score 2.2) and is not considered in the following discussion. TF binds to nascent protein chains on the ribosome. It is ATP-independent and does not require a co-chaperone. TF is composed of an N-terminal ribosome-binding domain, a PPIase domain and a C-terminal domain that shows structural homology to MPN555 and SurA (Ferbitz *et al.*, 2004). Similarly to SurA, PPIase activity is not essential for nascent chain binding and the chaperone activity of trigger factor (Kramer *et al.*, 2004). The fused N-terminal and C-terminal domains provide trigger factor with almost wild-type-like chaperone activity *in vivo* and *in vitro*. The two domains form a cradle with a back and two 'arms' that has the capacity to bind peptide fragments. Analysis of the crystal packing reveals that a neighbouring molecule inserts an α -helix and β -strand between the 'arms' of the C-terminal domain (Ferbitz *et al.*, 2004). The structures of MPN555 and the C-terminal domain of trigger factor show clear similarity (Fig. 4b). Lobe 1 in MPN555 corresponds to the 'back' of the trigger-factor

domain and lobes 2 and 3 of MPN555 correspond to the 'arms' of the trigger factor.

The structural similarities of MPN555 to SurA and *E. coli* trigger factor and the observed binding of the N-terminal tag in the MPN555 binding pocket all suggest a chaperone function for MPN555. This would also explain the low sequence conservation. The overall shape and surface distribution of hydrophobic patches are more likely to be critical for substrate binding than particular side chains, because molecular chaperones need to be able to bind a diverse set of peptides. The structural results and analysis from this study can direct future biochemical studies to further explore and possibly confirm the protein's function.

We thank Dr P. Adams for helpful discussions concerning the structure determination and refinement of the protein. The work described here was supported by the National Institutes of Health grant GM 62412.

References

- Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D. J. (1997). *Nucleic Acids Res.* **25**, 3389–3402.
- Baker, N. A., Sept, D., Joseph, S., Holst, M. J. & McCammon, J. A. (2001). *Proc. Natl Acad. Sci. USA*, **98**, 10037–10041.
- Bateman, A., Birney, E., Durbin, R., Eddy, S. R., Howe, K. L. & Sonnhammer, E. L. L. (2000). *Nucleic Acids Res.* **28**, 263–266.
- Behrens, S., Maier, R., de Cock, H., Schmid, F. X. & Gross, C. A. (2001). *EMBO J.* **20**, 285–294.
- Bitto, E. & McKay, D. B. (2002). *Structure*, **10**, 1489–1498.
- Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T. & Warren, G. L. (1998). *Acta Cryst.* **D54**, 905–921.
- Collaborative Computational Project, Number 4 (1994). *Acta Cryst.* **D50**, 760–763.
- DeLano, W. L. (2002). *The PyMOL Molecular Graphics System*. DeLano Scientific, San Carlos, CA, USA. <http://www.pymol.org>.
- Ferbitz, L., Maier, T., Patzelt, H., Bukau, B., Deuerling, E. & Ban, N. (2004). *Nature (London)*, **431**, 590–596.
- Grosse-Kunstleve, R. W. & Adams, P. D. (2003). *Acta Cryst.* **D59**, 1966–1973.
- Holm, L. & Sander, C. (1996). *Methods Enzymol.* **266**, 653–62.
- Jancarik, J. & Kim, S.-H. (1991). *J. Appl. Cryst.* **24**, 409–411.
- Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M. (1991). *Acta Cryst.* **A47**, 110–119.
- Kim, R., Sandler, S. J., Goldman, S., Yokota, H., Clark, A. J. & Kim, S.-H. (1998). *Biotechnol. Lett.* **20**, 207–210.
- Kramer, G., Patzelt, H., Rauch, T., Kurz, T. A., Vorderwulbecke, S., Bukau, B. & Deuerling, E. (2004). *J. Bacteriol.* **186**, 3777–3784.
- Ludlam, V. L., Moore, B. A. & Xu, Z. (2004). *Proc. Natl Acad. Sci.* **101**, 13436–13441.
- Murshudov, G. N., Vagin, A. A. & Dodson, E. J. (1997). *Acta Cryst.* **D53**, 240–255.
- Studier, F.W. (2005). *Protein Expr. Purif.* **41**, 207–234.
- Terwilliger, T. C. (2002). *Acta Cryst.* **D58**, 1937–1940.